• Return to Headlines

Shares of Neos Therapeutic Rank the Lowest in Terms of Return on Equity in the Pharmaceuticals Industry (NEOS, NKTR, NBY, MDCO, TBPH)

By Amy Schwartz

Below are the three companies in the Pharmaceuticals industry with the lowest return on equity. The ROE is a general indication of the company's efficiency; investors usually look for companies with ROEs that are high and are growing.

Neos Therapeutic ranks lowest with a ROE of -46,013.5%. Nektar Therapeut is next with a ROE of -24,966.6%. Novabay Pharmaceuticals Inc ranks third lowest with a ROE of -20,874.9%.

Medicines Comp follows with a ROE of -17,771.8%, and Theravance B rounds out the bottom five with a ROE of -15,960.3%.

SmarTrend recommended that subscribers consider buying shares of Medicines Comp on November 19th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $70.84. Since that recommendation, shares of Medicines Comp have risen 19.9%. We continue to monitor Medicines Comp for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest return on equity neos therapeutic nektar therapeut :nby novabay pharmaceuticals inc medicines comp theravance b

Ticker(s): NEOS NKTR MDCO TBPH